Department of Oncology, Beijing Chaoyang San Huan Cancer Hospital, Beijing, China.
State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Thorac Cancer. 2022 Nov;13(21):3063-3067. doi: 10.1111/1759-7714.14636. Epub 2022 Sep 12.
Neuregulin 1 (NRG1) gene fusion is a rare oncogenic driver gene in multiple tumor types, leading to the activation of the epidermal growth factor receptor (ErbB)-mediated pathway. Therefore, afatinib, a pan-ErbB family inhibitor, may be a therapeutic candidate for NRG1 fusion-driven tumors. In this case, we report a multiple primary lung adenocarcinoma patient harboring the CD74-NRG1 fusion, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (ERBB2) mutation simultaneously. The patient received afatinib and pyrotinib combination therapy and showed a significant treatment response with a progression-free survival of 5 months. Our case further supports the use of targeted therapy for NRG1 fusion-positive non-small-cell lung cancer.
神经调节蛋白 1（NRG1）基因融合是多种肿瘤类型中罕见的致癌驱动基因，导致表皮生长因子受体（ErbB）介导的途径激活。因此，泛 ErbB 家族抑制剂阿法替尼可能是 NRG1 融合驱动肿瘤的治疗候选药物。在本例中，我们报告了一例同时携带 CD74-NRG1 融合、表皮生长因子受体（EGFR）和人表皮生长因子受体 2（ERBB2）突变的多原发肺腺癌患者。该患者接受了阿法替尼和吡咯替尼联合治疗，无进展生存期为 5 个月，显示出显著的治疗反应。我们的病例进一步支持针对 NRG1 融合阳性非小细胞肺癌的靶向治疗。
